Two Sigma Investments
RARE icon

Two Sigma Investments’s Ultragenyx Pharmaceutical RARE Stock Holding History

Two Sigma Investments’s Portfolio RARE Stock Details RARE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$46.2M Buy
2,205,820
+1,781,771
+420% +$40.1M 0.04% 531
2025
Q4 		$9.75M Buy
424,049
+97,869
+30% +$3.22M 0.01% 1138
2025
Q3 		$9.81M Sell
326,180
-250,721
-43% -$7.52M 0.01% 970
2025
Q2 		$21M Sell
576,901
-56,251
-9% -$2.03M 0.04% 538
2025
Q1 		$22.9M Buy
633,152
+18,204
+3% +$757K 0.05% 437
2024
Q4 		$25.9M Sell
614,948
-140,735
-19% -$6.98M 0.06% 405
2024
Q3 		$42M Buy
755,683
+187,374
+33% +$9.54M 0.09% 272
2024
Q2 		$23.4M Buy
568,309
+152,995
+37% +$6.53M 0.05% 412
2024
Q1 		$19.4M Buy
415,314
+288,704
+228% +$13.6M 0.05% 450
2023
Q4 		$6.05M Buy
126,610
+87,410
+223% +$3.39M 0.01% 886
2023
Q3 		$1.4M Sell
39,200
-364,574
-90% -$14.4M ﹤0.01% 1726
2023
Q2 		$18.6M Sell
403,774
-84,582
-17% -$3.92M 0.05% 427
2023
Q1 		$19.6M Buy
488,356
+46,420
+11% +$1.99M 0.06% 384
2022
Q4 		$20.5M Buy
441,936
+186,547
+73% +$7.34M 0.06% 349
2022
Q3 		$10.6M Buy
255,389
+198,889
+352% +$10.2M 0.04% 478
2022
Q2 		$3.37M Buy
56,500
+17,600
+45% +$1.08M 0.01% 930
2022
Q1 		$2.83M Buy
+38,900
New +$2.71M 0.01% 1186
2021
Q4 		– Sell
-25,900
Closed -$2.34M – 4766
2021
Q3 		$2.34M Sell
25,900
-264,364
-91% -$23.9M 0.01% 1852
2021
Q2 		$27.7M Buy
290,264
+145,944
+101% +$15.2M 0.06% 383
2021
Q1 		$16.4M Buy
144,320
+84,008
+139% +$11.4M 0.04% 505
2020
Q4 		$8.35M Buy
60,312
+54,595
+955% +$6.48M 0.02% 670
2020
Q3 		$470K Sell
5,717
-33,837
-86% -$2.8M ﹤0.01% 2294
2020
Q2 		$3.09M Buy
+39,554
New +$2.62M 0.02% 886
2019
Q4 		– Sell
-7,759
Closed -$332K – 3929
2019
Q3 		$332K Buy
+7,759
New +$422K ﹤0.01% 2894
2015
Q4 		– Sell
-150,113
Closed -$14.5M – 2928
2015
Q3 		$14.5M Buy
150,113
+4,772
+3% +$546K 0.07% 288
2015
Q2 		$14.9M Buy
145,341
+132,520
+1,034% +$10.3M 0.07% 333
2015
Q1 		$796K Buy
+12,821
New +$712K ﹤0.01% 1716

Other funds holding RARE

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

Two Sigma Investments's RARE Position: Q1 2026 in Review

Two Sigma Investments increased its Ultragenyx Pharmaceutical (RARE) stake by 420% in Q1 2026, buying an estimated $40.1M and bringing the position to 2,205,820 shares worth $46.2M. The position accounts for 0.04% of the portfolio, ranked #531.

Two Sigma Investments first reported a position in RARE in Q1 2015 and has held it in 27 quarters since. 295 funds tracked by Wall St. Rank hold RARE as of Q1 2026.

  • Two Sigma Investments held 2,205,820 shares of Ultragenyx Pharmaceutical worth $46.2M as of Q1 2026.
  • Two Sigma Investments bought 1,781,771 Ultragenyx Pharmaceutical shares in Q1 2026, an estimated $40.1M.
  • Ultragenyx Pharmaceutical made up 0.04% of Two Sigma Investments's portfolio in Q1 2026, its #531 holding.
  • Two Sigma Investments first reported a position in Ultragenyx Pharmaceutical in Q1 2015 and has held it in 27 quarters since.
  • 295 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q1 2026.

Based on Two Sigma Investments's 13F filing for Q1 2026, filed 15 May 2026.